Table 3 Drug compliance and drug associated adverse events
| Â | PACB | PAC | p-value |
|---|---|---|---|
Incidence of AE (ITT) (/n = 118) | 39.0% | 35.6% |  |
Drug compliance | (n = 115) | (n = 109) |  |
Taking > 85% | 113 (98.3) | 107 (98.2) | 0.957 |
Taking less than 85% | 2 (1.7) | 2 (1.8) | Â |
Severity of AE | (n = 115) | (n = 109) |  |
None | 72 (62.6) | 76 (69.7) | 0.347 |
Present but tolerable | 43 (37.4) | 32 (29.4) | Â |
Intolerable and need to stop taking | 0 | 1 (0.9) | Â |
AE characteristics | (n = 115) | (n = 109) |  |
Nausea-vomiting | 8 (7.1) | 2 (1.8) | 0.102 |
Loose stool | 18 (15.9) | 1 (0.9) |  > 0.001 |
Constipation | 1 (0.9) | 0 | 1.000 |
Headache | 4 (3.5) | 0 | 0.122 |
Metallic taste | 8 (7.1) | 1 (0.9) | 0.036 |
Indigestion | 3 (2.7) | 0 | 0.247 |
General weakness | 1 (0.9) | 0 | 1.000 |
Epigastric soreness | 3 (2.7) | 0 | 0.247 |
Indescribable non-specific discomfort | 10 (8.8) | 28 (25.7) | 1.000 |